focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
So after all that wyndrum, and btw you have contradicted yourself again on what info the market has access to or not and also now pivoted from “the wrapper might be inhibiting dox” to “ the science works but Avacta might be taken private for 100p”, but the question still remains and I’ll paste it back for your convenience:
so, which is it wyndrum? Is the current share price a vote of confidence by investors in the know, or a bunch of clueless opportunists taking advantage of a 50p placing that should be ignored as far as the validity of ava6000 and precision is concerned?
From the fusion press release:
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its clinical stage FPI-2059, a neurotensin receptor 1 (NTSR1) targeted alpha therapy (TAT), and additional preclinical development programs. The Company presented these data in three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting.
i'm not trying to shut down alternative scenarios (although the wrapper inhibiting dox is a bit a far fetched), i was just pointing out that your definition of the market and what it represents is inconsistent, which actually sums up your use of the market as some kind of justification for your sentiment (read: your trading position).
if you look at the "market" back in oct/nov it was trading as high as 166p. so at that point was the market, with all its combined expertise and wisdom, in the know about the potential of what ava6000 could deliver? back in july 23 it was down at 88p. so was the market convinced at that point that ava6000 had no future? go back a bit further feb 23 and it was up at 180p. **** me, does the market know or does it not know, or, and this is more likely, do the swings just represent the oscillations of the trading fraternity until there is more concrete or definitive proof from the trials?
the current sp doesn't necessarily tell us anything about the science, perhaps all it does it reflect the fact that the placing was offered to a bunch of opportunist financiers who were let in at 50p, and the descent to 50p was just those anticipating a placing before any further significant news events. so long as there is sufficient time before the trial completes, the vacuum will be traded and we'll see peaks and troughs.
it is therefore you trying to suggest that the current share price should be taken as a bell weather of the success of the tech or the trial is where i take exception. if the participating funds were dumb and opportunistic, as has been discussed here today, then their opinion is irrelevant. if however they are knowledgeable and they still threw a few millions at avacta, then that would still be hugely significant. no institution with any significant reputation or integrity is going to pour millions down a hole, even if it were at 50p. if precision is gubbins, then it could still end up at 5p.
so, which is it wyndrum? a vote of confidence by investors in the know, or a bunch of clueless opportunists taking advantage of a 50p placing that should be ignored as far as the validity of ava6000 and precision is concerned?
Access to capital markets isn't limited to II's. The PI base could have been tapped into numerous times. I think our nominated "advisors" have a lot to answer for here, no doubt whispering in avacta's ear that it couldn't be pulled off without the help of professional money, and at the same time giving the chaps in straps a nod and a wink.
Wyndrum, we already went over the market angle. Remember, the Oliver Brown fund? They freely admitted that they were clueless about the science and were only interested in undercutting the PI's and the current share price.
Dox is being inhibited by the wrapper now is it? 😕 That's a pretty desperate angle, got the intern on the wyndrum account today?
If people suffer from 1 or n types of cancer they are all eligible for the same treatment, no? So the market size is not dependent on the number of different types a person happens to suffer from.
I don't think you can screen for patients and then just put them hold whilst you sort your funding out. My feeling is there could be a challenge in persuading patients that are at the start of their treatment program to got with what is an experimental treatment. I'm just speculating of course.
From the RNS entitled "Proposed Fundraise to progress Therapeutics":
"The dose expansions are expected to be in several orphan indications including soft tissue sarcomas and the selection of these dose expansion indications will be informed by data from the ongoing two-weekly and three-weekly dose escalation studies."
and
"Given the favourable safety data from the three-weekly Phase 1a dosing study, a two-weekly dosing study, which is now screening patients with high FAP levels in the USA, will assist in optimising the schedule and dose for a Phase 2 study"
Can we take from this patients are currently being both screened and dosed on a 2w regimen?
Yes Bella, this can be the only justification for me to have done the raise down at 50p, that is to get specialist funds on board that can open doors. The "Oliver Brown" funds of this world are just leeching off PI's and I sincerely hope that the whole fundraise wasn't comprised of this calibre of fund.
So what happened to wyndrums post in this where they suggested I was just trying to trip them up rather than having a discussion about the SP? How was this selectively removed and why tf was it removed?